Section Arrow
Quote
BIAF.NASDAQ
- bioAffinity Technologies
(Financial Status)
Quotes are at least 15-min delayed:2025/07/03 04:04 EDT
Last
 0.29
+0.0265 (+10.06%)
Day High 
0.3547 
Prev. Close
0.2635 
1-M High
0.46 
Volume 
5.13M 
Bid
0.275
Ask
0.31
Day Low
0.2593 
Open
0.2593 
1-M Low
0.2243 
Market Cap 
7.50M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.27 
20-SMA 0.28 
50-SMA 0.31 
52-W High 2.9893 
52-W Low 0.1639 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.71/--
Enterprise Value
8.31M
Balance Sheet
Book Value Per Share
0.05
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
9.36M
Operating Revenue Per Share
0.00
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NEOGNeogen Corp5.23+0.15+2.95%879PE
BIAFbioAffinity Technologies0.29+0.0265+10.06%-- 
DHRDanaher Corp202.5+1.4+0.70%38.97PE
OPKOPKO Health1.34+0.01+0.75%-- 
TMOThermo Fisher Scientific427.76+6.29+1.49%24.72PE
Quotes are at least 15-min delayed：2025/07/03 04:04 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.